Hapoalim Cutting Ocverage On Multitude Of Names

Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure.

The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ: AMRN) Amylin (NASDAQ: AMLN) Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL), Biospecifics (NASDAQ: BSTC), Cephalon (NASDAQ: CEPH), MannKind (NASDAQ: MNKD), Medivation (NASDAQ: MDVN), Nektar (NASDAQ: NKTR), Neurocrine Biosciences (NASDAQ: NBIX), Protalix (NYSE: PLX) Targacept (NASDAQ: TRGT), and Vanda Pharmaceuticals (NASDAQ: VNDA).